Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Cervicovaginal Mucosal Inflammation
NCT01593124Phase 2Completed
- Sponsor
- CONRAD
- Start
- May 2012
- Primary completion
- Apr 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imiquimod and nonoxynol-9 (2 arms), sponsored by CONRAD. Primary endpoint: Differential Microarray gene expression. Started May 2012; status: completed.
02
Drugs
imiquimodnonoxynol-9
Beyond the preview
Go deeper on NCT01593124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593124.